Michelle Petri

73.4k total citations · 10 hit papers
534 papers, 33.5k citations indexed

About

Michelle Petri is a scholar working on Rheumatology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Michelle Petri has authored 534 papers receiving a total of 33.5k indexed citations (citations by other indexed papers that have themselves been cited), including 466 papers in Rheumatology, 256 papers in Immunology and 120 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Michelle Petri's work include Systemic Lupus Erythematosus Research (460 papers), Monoclonal and Polyclonal Antibodies Research (115 papers) and Atherosclerosis and Cardiovascular Diseases (113 papers). Michelle Petri is often cited by papers focused on Systemic Lupus Erythematosus Research (460 papers), Monoclonal and Polyclonal Antibodies Research (115 papers) and Atherosclerosis and Cardiovascular Diseases (113 papers). Michelle Petri collaborates with scholars based in United States, United Kingdom and Canada. Michelle Petri's co-authors include Laurence S. Magder, Daniel J. Wallace, William W. Freimuth, Joan T. Merrill, Z. John Zhong, Ellen M. Ginzler, Jill P. Buyon, Megan E. B. Clowse, Andrea Fava and Frank R. Witter and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Michelle Petri

526 papers receiving 32.6k citations

Hit Papers

Efficacy and safety of belimumab in patients... 1997 2026 2006 2016 2011 2011 2005 1997 2018 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
    2011 1.4k citations A Gallacher, Stephen Hall et al. profile →
  2. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
    2011 1.1k citations Richard Furie, Michelle Petri et al. Arthritis & Rheumatism profile →
  3. Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
    2005 766 citations Ellen M. Ginzler, Cynthia Aranow et al. profile →
  4. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index in patients with Systemic Lupus Erythematosus
    1997 587 citations Dafna D. Gladman, Murray B. Urowitz et al. Arthritis & Rheumatism profile →
  5. Systemic lupus erythematosus: Diagnosis and clinical management
    2018 455 citations Andrea Fava, Michelle Petri profile →
  6. Management strategies and future directions for systemic lupus erythematosus in adults
    2019 427 citations Michelle Petri et al. profile →
  7. Predictors of Pregnancy Outcomes in Patients With Lupus
    2015 359 citations Michelle Petri, D. Ware Branch et al. profile →
  8. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
    2018 356 citations Daniel J. Wallace, Richard Furie et al. profile →
  9. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)
    2023 89 citations Michelle Petri, Ian N Bruce et al. profile →
  10. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)
    2023 79 citations Michelle Petri, Daniel J. Wallace et al. profile →

Peers

Michelle Petri
Comparison fields: 5 of 161
  • Rheumatology 25.7k
  • Immunology 16.7k
  • Radiology, Nuclear Medicine and Imaging 7.3k
  • Pathology and Forensic Medicine 3.8k
  • Hematology 3.2k
Replace Munther A. Khamashta with:
Munther A. Khamashta United Kingdom
Pier Luigi Meroni Italy
Ricard Cervera Spain
Dennis J. McShane United States
Dafna D. Gladman Canada
Murray B. Urowitz Canada
Jane G. Schaller United States
Ronald van Vollenhoven Sweden
Caroline Gordon United Kingdom
Anǵela Tincani Italy
Munther A. Khamashta United Kingdom View profile →
Citations per field, relative to Michelle Petri
Michelle Petri · 1×
Citations per year, relative to Michelle Petri
Michelle Petri · 1×

Countries citing papers authored by Michelle Petri

Since Specialization
Citations

This map shows the geographic impact of Michelle Petri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle Petri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle Petri more than expected).

Fields of papers citing papers by Michelle Petri

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle Petri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle Petri. The network helps show where Michelle Petri may publish in the future.

Co-authorship network of co-authors of Michelle Petri

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle Petri. A scholar is included among the top collaborators of Michelle Petri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle Petri. Michelle Petri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Anti-TFAM antibodies link mitochondrial damage with antiphospholipid syndrome and thrombosis in SLE
2025 ·Annals of the Rheumatic Diseases ·Eduardo Gómez-Bañuelos, (unknown), (unknown), (unknown), (unknown), Shruti Chaturvedi, Fabrizio Conti, Cristiano Alessandri, Eleni Tiniakou, Daniel Goldman, Robert A. Brodsky, Michelle Petri, Felipe Andrade
1
2
Hydroxychloroquine Improves Low Complement Levels
2024 ·Arthritis Care & Research ·(unknown), Daniel Goldman, Andrea Fava, Laurence S. Magder, Michelle Petri
2
3
Urine L-selectin reflects clinical and histological renal disease activity and treatment response in lupus nephritis across multi-ethnicity
2023 ·Frontiers in Immunology ·(unknown), Kamala Vanarsa, Zhihua Yin, Ting Zhang, (unknown), Min Dai, (unknown), Ling Qin, (unknown), Qiang Guo, Ramesh Saxena, Michelle Petri, Nan Shen, Zhizhong Ye, Chandra Mohan, Huihua Ding
3
4
Fluctuation of Anti–Domain 1 and Anti–β2‐Glycoprotein I Antibody Titers Over Time in Patients With Persistently Positive Antiphospholipid Antibodies
2023 ·Arthritis & Rheumatology ·Cecilia Beatrice Chighizola, Francesca Pregnolato, Danieli Andrade, Maria G. Tektonidou, Vittorio Pengo, Guillermo Ruiz‐Irastorza, H. Michael Belmont, Maria Gerosa, Paul R. Fortin, D. Ware Branch, Laura Andréoli, Michelle Petri, Ricard Cervera, Jason S. Knight, Rohan Willis, Maria Efthymiou, Hannah Cohen, Doruk Erkan, María Laura Bertolaccini
12
5
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks
2023 ·Lupus Science & Medicine ·Binod Neupane, (unknown), Mahmoud Slim, Amber Martin, Michelle Petri, George Βertsias, Alfred H.J. Kim, Antonis Fanouriakis, Roger A. Levy, (unknown), Nick Ballew
9
6
Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data
2022 ·Lupus Science & Medicine ·Megan E. B. Clowse, Amanda M. Eudy, Stephen J. Balevic, (unknown), Andrzej S. Kosinski, Rebecca Fischer‐Betz, Dafna D. Gladman, Yair Molad, Cecilia Nalli, Abir Mokbel, Anǵela Tincani, Murray B. Urowitz, (unknown), Megan Van Noord, Michelle Petri
39
7
Clinical and histopathological features of myositis in systemic lupus erythematosus
2022 ·Lupus Science & Medicine ·Eleni Tiniakou, Daniel Goldman, Andrea M. Corse, Andrew L. Mammen, Michelle Petri
16
8
Scoring personalized molecular portraits identify Systemic Lupus Erythematosus subtypes and predict individualized drug responses, symptomatology and disease progression
2022 ·Briefings in Bioinformatics ·Daniel Toro‐Domínguez, Jordi Martorell‐Marugán, Manuel Martínez‐Bueno, Raúl López-Domínguez, Elena Carnero‐Montoro, Guillermo Barturen, Daniel Goldman, Michelle Petri, Pedro Carmona‐Sáez, Marta E. Alarcón‐Riquelme
23
9
Renal response at 2 years post biopsy to predict long-term renal survival in lupus nephritis: a retrospective analysis of the Hopkins Lupus Cohort
2022 ·Lupus Science & Medicine ·(unknown), Qinggong Fu, Yulia Green, (unknown), Patricia Juliao, Daniel Goldman, David A. Roth, Michelle Petri
6
10
Deconvoluting virome-wide antibody epitope reactivity profiles
2021 ·EBioMedicine ·Daniel R. Monaco, Sanjay Kottapalli, Florian P. Breitwieser, Danielle E. Anderson, Limin Wijaya, Kevin Tan, Wan Ni Chia, Kai Kammers, Patrizio Caturegli, Kathleen Waugh, Mario Roederer, Michelle Petri, Daniel Goldman, Marian Rewers, Lin‐Fa Wang, H. Benjamin Larman
24
11
Differential Treatments Based on Drug-induced Gene Expression Signatures and Longitudinal Systemic Lupus Erythematosus Stratification
2019 ·Scientific Reports ·Daniel Toro‐Domínguez, Raúl López-Domínguez, Adrián García-Moreno, Juan Antonio Villatoro-García, Jordi Martorell‐Marugán, Daniel Goldman, Michelle Petri, Daniel Wojdyla, Bernardo A. Pons‐Estel, David Isenberg, (unknown), (unknown), (unknown), Florencia Rosetti, Diana Gómez‐Martín, Juanita Romero‐Díaz, Pedro Carmona‐Sáez, Marta E. Alarcón‐Riquelme
25
12
Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus
2019 ·Arthritis & Rheumatology ·Daniel J. Wallace, Ellen M. Ginzler, Joan T. Merrill, Richard Furie, William Stohl, Winn Chatham, Arthur Weinstein, James D. McKay, W. Joseph McCune, Michelle Petri, James Fettiplace, David A. Roth, Beulah Ji, Amy Heath
84
13
Quantifying the burden of steroid-related damage in SLE in the Hopkins Lupus Cohort
2018 ·Lupus Science & Medicine ·Julie Davidson, Qinggong Fu, (unknown), Laurence S. Magder, Michelle Petri
25
14
Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines
2018 ·Arthritis Research & Therapy ·April Jorge, Ronald B. Melles, Yuqing Zhang, Na Lu, K. Sharan, Lucy H. Young, Karen H. Costenbader, Rosalind Ramsey‐Goldman, S. Sam Lim, John M. Esdaile, Ann E. Clarke, Murray B. Urowitz, Anca Askanase, Cynthia Aranow, Michelle Petri, Hyon K. Choi
32
15
Derivation and Validation of Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus
2011 ·Carolina Digital Repository (University of North Carolina at Chapel Hill) ·Michelle Petri, (unknown), (unknown), Caroline Gordon, JT Merrill, Paul R. Fortin, Ian N Bruce, David Isenberg, (unknown), Ola Nived, G Sturfelt, Rosalind Ramsey‐Goldman, Sang‐Cheol Bae, (unknown), Jorge Sánchez‐Guerrero, A. Clarke, Cynthia Aranow, (unknown), (unknown), (unknown), Kenneth Kalunian, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)
1
16
Late‐breaking abstracts: American College of Rheumatology 2009 Annual Scientific Meeting
2009 ·Arthritis & Rheumatism ·(unknown), A Gallacher, Roger A. Levy, (unknown), Mathew Thomas, Roland Jimenez, M.B. Leon, Stephen Hall, Joung‐Liang Lan, Е. Л. Насонов, C Tănăsescu, (unknown), (unknown), (unknown), William W. Freimuth, Michelle Petri, (unknown), (unknown)
4
17
Pancreatitis in Systemic Lupus Erythematosus: Frequency and Associated Factors — A Review of the Hopkins Lupus Cohort
2009 ·The Journal of Rheumatology ·Ashima Makol, Michelle Petri
46
18
Predictors of carotid atherosclerosis in systemic lupus erythematosus.
2006 ·PubMed ·Kathleen Maksimowicz‐McKinnon, Laurence S. Magder, Michelle Petri
68
19
Celecoxib effectively treats patients with acute shoulder tendinitis/bursitis.
2004 ·PubMed ·Michelle Petri, (unknown), (unknown), Harry Cui, Michael C. Snabes, Kenneth M. Verburg
36
20
Autoantibody tests in autoimmune thyroid disease: a case-control study.
1991 ·PubMed ·Michelle Petri, Elizabeth W. Karlson, David S. Cooper, Paul W. Ladenson
42

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Munther A. Khamashta Breakdown of academic impact, for papers by Pier Luigi Meroni Breakdown of academic impact, for papers by Ricard Cervera Breakdown of academic impact, for papers by Dennis J. McShane Breakdown of academic impact, for papers by Dafna D. Gladman Breakdown of academic impact, for papers by Murray B. Urowitz Breakdown of academic impact, for papers by Jane G. Schaller Breakdown of academic impact, for papers by Ronald van Vollenhoven Breakdown of academic impact, for papers by Caroline Gordon Breakdown of academic impact, for papers by Anǵela Tincani
Rankless by CCL
2026